SKYSONA

This brand name is authorized in Estonia, France, Lithuania, Poland

Active ingredients

The drug SKYSONA contains one active pharmaceutical ingredient (API):

1 Elivaldogene autotemcel UNII KUM75TD6SG - ELIVALDOGENE AUTOTEMCEL

Elivaldogene autotemcel is indicated for the treatment of early cerebral adrenoleukodystrophy in patients less than 18 years of age, with an ABCD1 genetic mutation. Elivaldogene autotemcel adds functional copies of the ABCD1 cDNA into patients' HSCs through transduction of autologous CD34+ cells with Lenti-D LVV. Following successful engraftment with genetically modified cells, the expression of ALDP is expected to be life-long. Read about Elivaldogene autotemcel

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
SKYSONA Dispersion for infusion	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
N07	Other nervous system drugs	N Nervous system
Discover more medicines within N07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1858596
Country: FR	Base de données publique des médicaments	Identifier(s): 65249832
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1093082
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100456917